The accuracy of fibrinogen and hs-crp as a biomarker in acute coronary syndrome (ACS)
AbstractBackground: acute coronary syndrome (ACS) refers to any group of clinical symptom compatible with acute myocardial infarction (AMI). AMI is a major cause of death and disability worldwide with the greates risk of death within the first hours of AMI onset. Thus, the identification of novel biomarkers that improve current strategies and/or accurately identify subjects who are at risk of developing acute and chronic manifestation of cardiovascuar disease are desperately needed.
Obsjective: this study was aimed to determine the accuracy diagnostic value of Fibrinogen and High Sensitivity C-Reactive Protein as a biomarker for Acute Coronary Syndrome
Subjects and methods: an observational study with cross sectional approach, was conducted from February to July 2011 involving 76 male and female patients aged 35 to 80 years old for cases all well as controls. The biomarker measured were level of Fibrinogen and Hs-CRP. We used Receiver Operating Curve to determine the cut off test. We calculated of sensitivity, specificity, likelihood ratio, negative predictive value, and postive predictive value for biomarkers in combination and single.
Results : the mean age in both groups was 57.5 year old. Level of the Fibrinogen in cases (5.8±1.56) was significantly different than control (3.78±1.78). concentration Hs-CRP in cases (4.04±1.94) was significantly different than control (1.98±1.25). both these biomarkers can be used as a diagnostic tool for Acute Coronary Syndrome in combination or single.
Conclusion : the combination of Fibrinogen and Hs-CRP has the better diagnostic value that when used single.
Schulman SP, Fessler HF. Management of Acute Coronary Syndromes. J Respiratory Critical Care Med. 2001. 164(6) : 917-922).
Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice. Circulation. 2003. 107 (3): 499-511.
Awecado M., Pearce G.L., Kottke-Marchant K., Sprecher D.L. Elevated Fibrinogen and Homocysteine levels enchance the risk of mortality in patient from a high risk preventive Cardiology clinic. Arterioscler Thromb Vasc Biol. 2002. 22:1024-1045.
Bucova M., Bernadic M., Buckingham T. C-Reactive Protein, Cytokines and Inflammation in Cardiovascular Disease., Bratislavia Lek Listy. 2008. 109(8):333-340.
Ben Khalfallah A, Sanaa I, Annabi N, Ousji M, Aloui H, Naffeti S. Predictive Value of The Markers of Inflammation In Acute Coronary Syndromes. Arch Mal Coeur Vaiss. 2005. 98(9).899-905.
Virani S.S, Polsani, V.R, Nambi, V. Novel markers of inflammation in atherosclerosis. 2008. 10(2) : 164-170.
Levenson, J., Giral, P., Razavian, M., Gariepy, J., Simon, A. Fibrinogen and silent atherosclerosis in subjects with cardiovascular risk factors. Arteriosclerosis, Thrombosis and Vasc Biol. 1995. 15: 1263-1269.
Haidari M, Javadi E, Sadeghi B. Evaluation of C-Reactive Protein, a sensitive marker of inflammation, as a risk factor for stable coronary artery diseases. Clin Biochem. 2001; 33: 309-15.
Dasgupta H, et al. Thrombocytopenia complicating treatment with Intravenous Glycoprotein Iib/IIIa receptors inhibitors : A Pooled Analysis. Am Heart J. 2000. 140(2) : 206-11.
Lauer MS. Primary prevention of atherosclerotic cardiovascular disease: the high public burden of low individual risk. JAMA. 2007. 297:1376–8.
Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L, for the FRISC Study Group. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. N Engl J Med. 2000. 343 (16): 1139-47.
Patel VB, Robbins MA, Topol EJ.. C-reactive protein: A ‘golden marker’ for inflammation and coronary artery disease. 2001. Claveland Clin J Med. 68(6) 521-534.
Littrell KA, Kern KB. Acute Ischemic Syndromes. Adjunctive Therapy. Cardiol Clin. 2002. 20(1) : 159-75.
Noordestgard BG, et al. Risk Factors for Near-Term Myocardial Infarction in Apparently Healthy Men and Women. 2010. Clinical Chem. 56(4) : 559–567.
Habib SS, et al. CRP Levels are Higher in Patients with ST Elevation Than Non-ST Elevation Acute Coronary Syndrome. Arq Bras Cardiol. 2011. 96(1): 13-17.
Ridker P, Hennekens C, Buring J, Rifai N. C-Reactive protein and Other Markers of Inflamation in The Prediction of Cardiovascular Disease. N England Journal Med. 2000. 342:836.
Pepys MB. C-reactive protein is neither a marker nor a mediator of atherosclerosis. Nat Clin Pract Nephrol. 2008. 4:234 –5.
Zouridakis E, Avanzas P, Arroyo-Espliguero R, Fredericks S, Kaski JC. Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris. Circulation. 2004; 110 (13): 1747-53.
Ware JH. The limitations of risk factors as prognostic tools. N Engl J Med. 2006. 355:2615.
Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR. C-reactive protein and parental history improve global cardiovascular risk prediction. The Reynolds Risk Score for men. Circulation. 2008. 118:2243–51.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).